Cargando…
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
BACKGROUND: This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. METHODS: A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of asse...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725679/ https://www.ncbi.nlm.nih.gov/pubmed/28944954 http://dx.doi.org/10.1002/bjs.10627 |
_version_ | 1783285581335232512 |
---|---|
author | Noble, F Lloyd, M A Turkington, R Griffiths, E O'Donovan, M O'Neill, J R Mercer, S Parsons, S L Fitzgerald, R C Underwood, T J Noorani, A Fels Elliott, R Abdullahi, Z de la Rue, R Bornschein, J MacRae, S Nutzinger, B Grehan, N Contino, G Crawte, J Edwards, P A W Miremadi, A Malhotra, S Hayden, A Walker, R Peters, C Hannah, G Hardwick, R Davies, J Ford, H Gilligan, D Safranek, P Hindmarsh, A Sujendran, V Carroll, N McManus, D Hayes, S J Ang, Y Preston, S R Oakes, S Bagwan, I Skipworth, R J E Save, V Hupp, T R Puig, S Bedford, M Taniere, P Whiting, J Byrne, J Kelly, J Owsley, J Crichton, C Barr, H Shepherd, N Old, O Lagergren, J Gossage, J Davies, A Chang, F Zylstra, J Sanders, G Berrisford, R Harden, C Bunting, D Lewis, M Cheong, E Kumar, B Saunders, J H Soomro, I N Vohra, R Duffy, J Kaye, P Grabowska, A Lovat, L Haidry, R Eneh, V Igali, L Welch, I Scott, M Sothi, S Suortamo, S Lishman, S Beardsmore, D Sutaria, R Secrier, M Eldridge, M D Bower, L Lynch, A G Tavaré, S |
author_facet | Noble, F Lloyd, M A Turkington, R Griffiths, E O'Donovan, M O'Neill, J R Mercer, S Parsons, S L Fitzgerald, R C Underwood, T J Noorani, A Fels Elliott, R Abdullahi, Z de la Rue, R Bornschein, J MacRae, S Nutzinger, B Grehan, N Contino, G Crawte, J Edwards, P A W Miremadi, A Malhotra, S Hayden, A Walker, R Peters, C Hannah, G Hardwick, R Davies, J Ford, H Gilligan, D Safranek, P Hindmarsh, A Sujendran, V Carroll, N McManus, D Hayes, S J Ang, Y Preston, S R Oakes, S Bagwan, I Skipworth, R J E Save, V Hupp, T R Puig, S Bedford, M Taniere, P Whiting, J Byrne, J Kelly, J Owsley, J Crichton, C Barr, H Shepherd, N Old, O Lagergren, J Gossage, J Davies, A Chang, F Zylstra, J Sanders, G Berrisford, R Harden, C Bunting, D Lewis, M Cheong, E Kumar, B Saunders, J H Soomro, I N Vohra, R Duffy, J Kaye, P Grabowska, A Lovat, L Haidry, R Eneh, V Igali, L Welch, I Scott, M Sothi, S Suortamo, S Lishman, S Beardsmore, D Sutaria, R Secrier, M Eldridge, M D Bower, L Lynch, A G Tavaré, S |
author_sort | Noble, F |
collection | PubMed |
description | BACKGROUND: This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. METHODS: A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging. RESULTS: TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2; median overall survival (OS) not reached) and non-responders (TRG 3–5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001). CONCLUSION: A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1–2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. |
format | Online Article Text |
id | pubmed-5725679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57256792017-12-12 Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma Noble, F Lloyd, M A Turkington, R Griffiths, E O'Donovan, M O'Neill, J R Mercer, S Parsons, S L Fitzgerald, R C Underwood, T J Noorani, A Fels Elliott, R Abdullahi, Z de la Rue, R Bornschein, J MacRae, S Nutzinger, B Grehan, N Contino, G Crawte, J Edwards, P A W Miremadi, A Malhotra, S Hayden, A Walker, R Peters, C Hannah, G Hardwick, R Davies, J Ford, H Gilligan, D Safranek, P Hindmarsh, A Sujendran, V Carroll, N McManus, D Hayes, S J Ang, Y Preston, S R Oakes, S Bagwan, I Skipworth, R J E Save, V Hupp, T R Puig, S Bedford, M Taniere, P Whiting, J Byrne, J Kelly, J Owsley, J Crichton, C Barr, H Shepherd, N Old, O Lagergren, J Gossage, J Davies, A Chang, F Zylstra, J Sanders, G Berrisford, R Harden, C Bunting, D Lewis, M Cheong, E Kumar, B Saunders, J H Soomro, I N Vohra, R Duffy, J Kaye, P Grabowska, A Lovat, L Haidry, R Eneh, V Igali, L Welch, I Scott, M Sothi, S Suortamo, S Lishman, S Beardsmore, D Sutaria, R Secrier, M Eldridge, M D Bower, L Lynch, A G Tavaré, S Br J Surg Original Article BACKGROUND: This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. METHODS: A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging. RESULTS: TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2; median overall survival (OS) not reached) and non-responders (TRG 3–5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001). CONCLUSION: A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1–2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. Oxford University Press 2017-09-25 /pmc/articles/PMC5725679/ /pubmed/28944954 http://dx.doi.org/10.1002/bjs.10627 Text en © 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Noble, F Lloyd, M A Turkington, R Griffiths, E O'Donovan, M O'Neill, J R Mercer, S Parsons, S L Fitzgerald, R C Underwood, T J Noorani, A Fels Elliott, R Abdullahi, Z de la Rue, R Bornschein, J MacRae, S Nutzinger, B Grehan, N Contino, G Crawte, J Edwards, P A W Miremadi, A Malhotra, S Hayden, A Walker, R Peters, C Hannah, G Hardwick, R Davies, J Ford, H Gilligan, D Safranek, P Hindmarsh, A Sujendran, V Carroll, N McManus, D Hayes, S J Ang, Y Preston, S R Oakes, S Bagwan, I Skipworth, R J E Save, V Hupp, T R Puig, S Bedford, M Taniere, P Whiting, J Byrne, J Kelly, J Owsley, J Crichton, C Barr, H Shepherd, N Old, O Lagergren, J Gossage, J Davies, A Chang, F Zylstra, J Sanders, G Berrisford, R Harden, C Bunting, D Lewis, M Cheong, E Kumar, B Saunders, J H Soomro, I N Vohra, R Duffy, J Kaye, P Grabowska, A Lovat, L Haidry, R Eneh, V Igali, L Welch, I Scott, M Sothi, S Suortamo, S Lishman, S Beardsmore, D Sutaria, R Secrier, M Eldridge, M D Bower, L Lynch, A G Tavaré, S Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title_full | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title_fullStr | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title_full_unstemmed | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title_short | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
title_sort | multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725679/ https://www.ncbi.nlm.nih.gov/pubmed/28944954 http://dx.doi.org/10.1002/bjs.10627 |
work_keys_str_mv | AT noblef multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lloydma multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT turkingtonr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT griffithse multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT odonovanm multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT oneilljr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT mercers multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT parsonssl multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT fitzgeraldrc multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT underwoodtj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT noorania multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT felselliottr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT abdullahiz multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT delaruer multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT bornscheinj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT macraes multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT nutzingerb multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT grehann multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT continog multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT crawtej multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT edwardspaw multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT miremadia multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT malhotras multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT haydena multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT walkerr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT petersc multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hannahg multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hardwickr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT daviesj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT fordh multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT gilligand multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT safranekp multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hindmarsha multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT sujendranv multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT carrolln multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT mcmanusd multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hayessj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT angy multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT prestonsr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT oakess multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT bagwani multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT skipworthrje multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT savev multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hupptr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT puigs multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT bedfordm multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT tanierep multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT whitingj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT byrnej multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT kellyj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT owsleyj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT crichtonc multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT barrh multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT shepherdn multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT oldo multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lagergrenj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT gossagej multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT daviesa multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT changf multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT zylstraj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT sandersg multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT berrisfordr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT hardenc multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT buntingd multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lewism multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT cheonge multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT kumarb multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT saundersjh multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT soomroin multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT vohrar multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT duffyj multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT kayep multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT grabowskaa multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lovatl multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT haidryr multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT enehv multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT igalil multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT welchi multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT scottm multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT sothis multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT suortamos multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lishmans multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT beardsmored multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT sutariar multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT secrierm multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT eldridgemd multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT bowerl multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT lynchag multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma AT tavares multicentrecohortstudytodefineandvalidatepathologicalassessmentofresponsetoneoadjuvanttherapyinoesophagogastricadenocarcinoma |